Van Amsterdam et al. present the first set of empirical findings relating to generic drug legislation in the UK and Germany, revealing it to be largely ineffective in counteracting NPS use and causing increased public health problems.
The EMCDDA shed light on emerging trends, challenges, and policy implications surrounding drug use in Europe up until the end of 2022, revealing high availability of substances and a greater need for harm reduction services.
The UK government plans to ban the sale of nitrous oxide, commonly known as laughing gas, despite independent advice suggesting that prohibition is not the most effective way to tackle its misuse.
Craft et al. find no clear evidence that exposure to analytically confirmed synthetic cannabinoids increased or decreased after implementing the Psychoactive Substances Act 2016.
The first issue of the magazine “Check” is dedicated to exploring the topic of new psychoactive substances, existing responses to the emergence of these substances and thoughts of peers from the EECA region.
UNODC presents a suite of videos explaining health interventions that seek to reduce harms among people who use stimulant drugs and new psychoactive substances.
EHRA provides an overview of NPS markets in the EECA region, assesses the state of related health provisions, and highlights pending challenges and avenues to address them.
